Market revenue in 2023 | USD 3,739.7 million |
Market revenue in 2030 | USD 6,795.9 million |
Growth rate | 8.9% (CAGR from 2023 to 2030) |
Largest segment | Macular degeneration |
Fastest growing segment | Diabetic Retinopathy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diabetic Retinopathy, Other Types, Macular Degeneration |
Key market players worldwide | Santen Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc, GrayBug, Takeda Pharmaceutical Co Ltd, Bayer AG, AbbVie Inc, Roche Holding AG ADR, Acucela, Pfizer Inc, Kubota Pharmaceutical Holdings |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to retinal disorder treatment market will help companies and investors design strategic landscapes.
Macular degeneration was the largest segment with a revenue share of 43.91% in 2023. Horizon Databook has segmented the Europe retinal disorder treatment market based on diabetic retinopathy, other types, macular degeneration covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe retinal disorder treatment market, including forecasts for subscribers. This continent databook contains high-level insights into Europe retinal disorder treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account